Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4- 1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – 18 sites open and recruiting across four Phase 1/2 RESET™ trials with 5 patients enrolled as ...